Show simple item record

dc.contributor.authorMahlangu, J. N.
dc.contributor.authorCoetzee, M. J.
dc.contributor.authorLaffan, M.
dc.contributor.authorWindyga, J.
dc.contributor.authorYee, T. T.
dc.contributor.authorSchroeder, J.
dc.contributor.authorHaaning, J.
dc.contributor.authorSiegel, J. E.
dc.contributor.authorLemm, G.
dc.date.accessioned2016-03-24
dc.date.accessioned2016-04-06T07:35:14Z
dc.date.available2012
dc.date.available2016-04-06T07:35:14Z
dc.date.issued2012
dc.identifier.citationMahlangu, J. N., Coetzee, M. J., Laffan, M., Windyga, J., Yee, T. T., Schroeder, J., ... & Lemm, G. (2012). Phase I, randomized, double‐blind, placebo‐controlled, single‐dose escalation study of the recombinant factor VIIa variant BAY 86‐6150 in hemophilia. Journal of Thrombosis and Haemostasis, 10(5), 773-780.en_ZA
dc.identifier.issn1538-7836
dc.identifier.urihttp://hdl.handle.net/11660/2379
dc.description.abstractBackground: BAY 86-6150 is a new human recombinant factor VIIa variant developed for high procoagulant activity and longer action in people with hemophilia with inhibitors. Objectives: To investigate the safety, tolerability, pharmacodynamics, pharmacokinetics and immunogenicity of BAY 86-6150 in non-bleeding hemophilia subjects. Methods: The study included non-bleeding men (18–65 years of age)withmoderate or severe hemophilia AorBwith or without inhibitors. Sixteen subjects were randomized 3 : 1 to four cohorts of escalating doses of BAY 86-6150 (6.5, 20, 50 or 90 lg kg)1 [n = 3 per cohort]) or placebo (n = 1 per cohort); an independent data-monitoring committee reviewed previous cohort data before the next dose escalation. Blood samplingwas performed predose and postdose; subjects were monitored for 50 days postdose. Results: At the tested doses, BAY 86-6150 was not associated with clinically significant adverse events or dose-limiting toxicities. BAY 86-6150 pharmacokinetics exhibited a linear dose response, with a half-life of 5–7 h. Subjects demonstrated consistent, dose-dependent thrombin generation ex vivo in platelet-poor plasma (PPP) (mean peak effect, 26– 237 nMthrombin from 6.5 to 90 lg kg)1). Peak thrombin levels over time paralleled BAY 86-6150, with thrombin kinetics appearing to be slightly shorter; thus, circulating BAY 86-6150 retained activity. There were corresponding decreases in activated partial thromboplastin and prothrombin times. No subject developed de novo anti-BAY 86-6150 neutralizing antibodies during the 50-day follow-up. Conclusions: In this first-in-human, multicenter, randomized, double-blind, placebo- controlled, single-dose escalation study, BAY 86-6150 was tolerated at the highest dose (90 lg kg)1), with no safety concerns. Safety and efficacy will be further evaluated in phase II/III studies.en_ZA
dc.language.isoenen_ZA
dc.publisherInternational Society on Thrombosis and Haemostasisen_ZA
dc.subjectHemophiliaen_ZA
dc.subjectRecombinant factor VIIa varianten_ZA
dc.subjectPharmacokineticsen_ZA
dc.titlePhase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophiliaen_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's versionen_ZA
dc.rights.holderInternational Society on Thrombosis and Haemostasisen_ZA


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record